Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 50:2136-2144, doi:10.1016/j.jacc.2007.07.078 (Published online 12 November 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Cardiosource Slide Set
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guazzi, M.
Right arrow Articles by Guazzi, M. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Guazzi, M.
Right arrow Articles by Guazzi, M. D.
Related Collections
Right arrowRelated Article

Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure

Marco Guazzi, MD, PhD, FACC*,*, Michele Samaja, PhD{dagger}, Ross Arena, PhD{ddagger}, Marco Vicenzi, MD* and Maurizio D. Guazzi, MD, PhD, FESC§

* Cardiopulmonary Unit, Cardiology Division
{dagger} Biochemistry Department, University of Milan, San Paolo Hospital, Milan, Italy
{ddagger} Virginia Commonwealth University, Richmond, Virginia
§ Institute of Cardiology, University of Milan, Milan, Italy


Figure 1
View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Study Design

Measurements at day –2 were performed at baseline, and those at day –1 were performed after a single oral dose of sildenafil (50 mg) in all participants. CHF = chronic heart failure; CPET = cardiopulmonary exercise testing.

 

Figure 2
View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Ergoreflex Assessment

Graphic expression of ventilation (VE) at rest (2 min), during handgrip (5 min), and during recovery (3 min) of metaboreflex test, in the baseline and after 3- and 6-month treatment in patients receiving placebo and in patients receiving sildenafil. *p < 0.01 versus no occlusion. §p < 0.01 versus patients receiving placebo.

 

Figure 3
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Correlation Analyses

Correlation analyses between brachial artery flow-mediated dilatation (FMD) and the ergoreflex component of the ventilatory response to handgrip at baseline in the placebo group (solid triangles) and in the sildenafil group (open triangles) as well as between changes of the 2 variables at 3- (open circles) and 6-month (solid circles) treatment. VE = ventilation.

 

Figure 4
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4 Correlation Analyses

Correlation analyses between changes from baseline in the ergoreflex component of the ventilatory response to handgrip and those in VE/VCO 2 slope and peak oxygen uptake (VO 2) in the placebo and sildenafil groups at 3- (open circles) and 6-month (solid circles) treatment. VCO 2 = carbon dioxide production; VE = ventilation.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement